



UNIVERSITY OF LEEDS

This is a repository copy of *Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/119692/>

Version: Supplemental Material

Article:

Lardas, M, Liew, M, van den Bergh, R et al. (21 more authors) (2017) Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. *European Urology*, 72 (6). pp. 869-885. ISSN 0302-2838

<https://doi.org/10.1016/j.eururo.2017.06.035>

(c) 2017, European Association of Urology. Published by Elsevier B.V. This manuscript version is made available under the CC BY-NC-ND 4.0 license
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 1a: Baseline characteristics of RCTs

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range]	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
Crook 2011 [11], North America, RCT-prospective, 2002-2004 EPIC	Radical prostatectomy	66	61.4 (6.2)	62.4 [38.4 – 78]	NR but inclusion criteria: either T1c or T2a	NR but inclusion criteria: ≤6	5.5 (2.1)	50% *
	Brachytherapy	102	59.4 (5.9)				5.3 (2.8)	*% of patients taking medications for Diabetes Mellitus, Hypertension or Cardiovascular disease
Donovan 2016 [12], UK, RCT, 1999-2009 EPIC EORTC QLQ-C30	Active monitoring	545	62 (5)	EORTC QLQ-C30 was assessed at 60 months EPIC was assessed at 72 months	T1c: 410 (75%) T2: 135 (25%)	6: 421 (77%) 7: 111 (20%) 8-10: 13 (2%) Missing: 0	4.7 [3.7-6.7]	NR
	Radical prostatectomy	553	62 (5)		T1c: 410 (74%) T2: 143 (26%)	6: 422 (76%) 7: 120 (22%) 8-10: 10 (2%) Missing: 1	4.9 [3.7-6.7]	
	Radiotherapy	545	62 (5)		T1c: 429 (79%) T2: 116 (21%)	6: 423 (78%) 7: 108 (20%) 8-10: 14 (3%) Missing: 0	4.8 [3.7-6.7]	
Giberti 2009 [13], Italy, RCT, 1999-2002	Radical prostatectomy	100	65.2 [57–74]	68.2 [60–102]	T1c: 64 (64%) T2a: 36 (36%)	5.9	7.8 [3.5-10]	NR

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range]	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
EORTC QLQ-C30 EORTC QLQ-PR25	Brachytherapy	100	65.6 [56-74]		T1c: 59 (59%) T2a: 41 (41%)	5.7	7.5 [2.9-9.3]	

NR: not reported